Infographic | May 31, 2022

Guidelines For Response Criteria For Use In Oncology Trials


Standardized Guidelines

The guidelines provide Baseline instructions for data collection/reporting. At Baseline, tumors and lesions will be categorized into measurable (target) and non-measurable (non-target). The target lesions must be accurately measured in at least one dimension (longest diameter in the plane of measurement to be recorded). Assessing tumor growth and cancer cell proliferation in patients is important for judging the effectiveness of individual treatment and for the evaluation of therapies in clinical trials. RECIST 1.1 provides a simple and pragmatic methodology to evaluate the activity and efficacy of new cancer therapeutics in solid tumors.

New Guidelines for Novel Cancer Treatments

The approval of intratumoral (IT) immunotherapy, the direct inoculation of immune-stimulating agents into the tumor itself, for metastatic melanoma and the active development of numerous novel IT drugs has created a need for standardized evaluation of response to this unique treatment strategy.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader